Navigation Links
Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
Date:12/7/2009

NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology ("ASH") Annual Meeting updated results from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL") patients who have failed 2 or more prior therapies. Updated analyses with additional follow-up data were conducted; these analyses and additional follow-up data support the initial clinical trial results. Subgroup analyses examining the effect of age, IPI score, disease status, or prior anthracycline doses on Progression Free Survival (PFS) demonstrated that pixantrone consistently improved PFS across subgroups compared with other chemotherapy agents. With patients in follow-up period at least 9 months from end of treatment, pixantrone provided a 250% relative improvement in 1 year PFS (21% Vs 6%) over comparator and a 115% increase in median overall PFS (5.6 months Vs 2.6 months, p=0.002, HR =0.56). The benefit on PFS was independent of risk factors. At 21 months, 14% of pixantrone patients remained free from disease progression versus 3% in the comparator arm.

"The results of the PIX301 trial continue to impress me as we gain additional follow-up data and information from exploratory sensitivity analyses," noted Dr. Ruth Pettengell, the principal investigator on the study. "The robustness of the drug's effect on prolonging progression free survival across all important risk factors lends to the strength and credibility of the clinical benefit provided to patients in the trial."

The PIX 301 EXTEND (Expanding the reach of anthracyclines with piXanTronE in relapsed or refractory aggressive Nhl <
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone
2. Pixantrone Now Available in Europe on a Named-Patient Basis
3. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
4. Pixantrone Overview in Non-Hodgkins Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference
5. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
6. Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe
7. FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
8. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
9. Stem cell research produces a key discovery for Fragile X Syndrome
10. Taxol with avastin produces noteworthy results
11. Aggressive Therapy for Crohns Disease Produces Better Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... March 28, 2015 Thousands of ... manufactured by C.R. Bard, Inc. continue to move ... District Court, Southern District of West Virginia, where ... on the Plaintiffs’ Steering Committee. According to ... granted certain defendants named in those lawsuits leave ...
(Date:3/28/2015)... India Network visitor health insurance announced ... visitors who purchase the plan before arrival in the ... purchase the insurance program as soon as travel plans ... pre-existing medical conditions. Parents and grandparents traveling from India ... serious consequences to their health. Many visitors may not ...
(Date:3/28/2015)... 28, 2015 Pitching speed, player’s height, and ... shoulder and elbow injuries, according to new research released today ... ) Specialty Day. , “Our findings indicate that a 10 ... in likelihood of a history of injury, a 10 mile ... increase likelihood of a history of injury, and playing for ...
(Date:3/28/2015)... March 28, 2015 Delaying rotator cuff ... necessary, according to research presented today at the American ... Day. , “Our study compared results for 170 patients ... an additional glenohumeral joint capsule release procedure to relieve ... MD, PhD, lead author from St. George Hospital in ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., ... posters. The Who and the Doors played together at the ... According to Hawley, “The Who toured the United States heavily ... campuses. Perhaps the most famous Who poster was a poster ... Doors on August 2, 1968 at the Singer Bowl in ...
Breaking Medicine News(10 mins):Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For&nbsp;Original 1960's Who Psychedelic Concert Posters. 2
... , , , ... Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it was ... to be submitted for a Marketing Authorization Application ("MAA") through the ... coordinated review for approval of pharmaceutical products that is conducted by ...
... health care reform measures, Rush University Medical Center has launched ... from hospital to home. The goal of ... two years ago, succeeds in reducing readmissions within 30 days ... model for hospitals across the country that are seeking ways ...
... DETROIT, July 28 Caraco Pharmaceutical Laboratories, Ltd. ... Doshi has been appointed as interim Chief Executive Officer and ... Daniel H. Movens as Chief Executive Officer and as a ... Movens, tenure, Caraco experienced substantial product expansion and revenue growth. ...
... is pondering, , TUESDAY, July 28 (HealthDay News) -- A ... raise the age at which American women should start Pap ... age at which a woman should first have a Pap ... States, however, women are told to get regular Pap smears ...
... do not appear to increase cancer risk. A large meta-analysis, published ... that snuff as used in Scandinavia has no discernible effect on ... the USA may have increased the risk, but any effect that ... and Jan Hamling, from P.N. Lee Statistics and Computing Ltd, carried ...
... , NEW YORK, July 28 Finding time to ... especially during stressful times. Here,s more on a how you can ... Listen to this report from Kellogg,s at: , ... can access video, audio, text, graphics and photos for free and unrestricted ...
Cached Medicine News:Health News:Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 2Health News:Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 3Health News:Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 4Health News:Rush University Medical Center studies program to help older adults transition from hospital to home 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO 2Health News:Teens May Not Benefit from Pap Tests 2Health News:Teens May Not Benefit from Pap Tests 3
(Date:3/27/2015)... March 27, 2015 /CNW/ - Covalon Technologies Ltd. (the ... company, today announced the issuance of an aggregate of ... Company and an aggregate of 120,500 stock options to ... will vest over three years and will be exercisable ... price of $1.40 per stock option. About ...
(Date:3/27/2015)... /PRNewswire/ - Medicure Inc. (the "Company") (TSXV:MPH, OTCQB:MCUJF) announces ... grant of an aggregate of 236,070 options to certain ... the Company pursuant to the Company,s Stock Option Plan. ... the tenth anniversary of the date of grant, 5,000 ... the date of grant and 50,000 are set to ...
(Date:3/27/2015)... , March 27, 2015  Holographic Optical Technologies ... the field of holographic medical imaging, is entering the ... Kickstarter campaign. Launching on April 20 th , 2015, ... Voxbox Pro. The 8-inch and 22-inch displays will allow ... for the first time. In addition to the two ...
Breaking Medicine Technology:Covalon Announces Issuance of Stock Options 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... 23, 2011 Reportlinker.com announces that a new ... Global Medical Imaging Equipment ... This report analyzes the worldwide ... Million by the following Product segments: OEM (Original ...
... announces that a new market research report is available ... Kits and Trays Industry http://www.reportlinker.com/p090645/Global-Prepackaged-Medical-Kits-and-Trays-Industry.html ... markets for Prepackaged Medical Kits and Trays in US$ ... Ophthalmic Custom Trays, Custom or Basin Kits, Custom Ob/Gyn, ...
Cached Medicine Technology:Reportlinker Adds Global Medical Imaging Equipment Services Industry 2Reportlinker Adds Global Prepackaged Medical Kits and Trays Industry 2
... comes with several blade sizes ... deep muscle retraction. The ... three different directions: medial, lateral ... optic light cable is compatible ...
Soft tissue shoulder retractor system...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
The ArthroPasser easily passes any type of suture through tissue and its smooth jaw assists in eliminating,suture fraying....
Medicine Products: